Cargando…

IFN-γ and CD38 in Hyperprogressive Cancer Development

SIMPLE SUMMARY: Hyperprogressive disease (HPD) is a pattern of paradoxical tumor progression that has been reported in patients treated with immune checkpoint inhibitors (ICIs). Although a large number of studies have investigated HPD and several associated factors have been reported, the mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angelicola, Stefania, Ruzzi, Francesca, Landuzzi, Lorena, Scalambra, Laura, Gelsomino, Francesco, Ardizzoni, Andrea, Nanni, Patrizia, Lollini, Pier-Luigi, Palladini, Arianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830527/ https://www.ncbi.nlm.nih.gov/pubmed/33467713 http://dx.doi.org/10.3390/cancers13020309

Ejemplares similares

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
por: De Giovanni, Carla, et al.
Publicado: (2019)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021)

Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
por: De Giovanni, Carla, et al.
Publicado: (2019)

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research
por: Landuzzi, Lorena, et al.
Publicado: (2023)

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(−/−);Il2rg(−/−) Mice and Treatment with PI3K Inhibitor
por: Nanni, Patrizia, et al.
Publicado: (2012)

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
por: Nanni, Patrizia, et al.
Publicado: (2019)

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
por: Landuzzi, Lorena, et al.
Publicado: (2014)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

Modeling the competition between lung metastases and the immune system using agents
por: Pennisi, Marzio, et al.
Publicado: (2010)

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
por: Sorrentino, Carlo, et al.
Publicado: (2022)

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2023)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Ectonucleotidase CD38 Demarcates Regulatory, Memory-Like CD8(+) T Cells with IFN-γ-Mediated Suppressor Activities
por: Bahri, Rajia, et al.
Publicado: (2012)

Increased TLR4 Expression Aggravates Sepsis by Promoting IFN-γ Expression in CD38(−/−) Mice
por: Li, Qi, et al.
Publicado: (2019)

The Promise of Preventive Cancer Vaccines
por: Lollini, Pier-Luigi, et al.
Publicado: (2015)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia
por: Murtadha, Mariam, et al.
Publicado: (2023)

Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27(−)CD38(+)IFN-γ(+)CD4(+) T cells for discrimination of active tuberculosis
por: Fang, Yong, et al.
Publicado: (2022)

Virus-like particle display of HER2 induces potent anti-cancer responses
por: Palladini, Arianna, et al.
Publicado: (2018)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Reduced Plasmodium Parasite Burden Associates with CD38(+) CD4(+) T Cells Displaying Cytolytic Potential and Impaired IFN-γ Production
por: Burel, Julie G., et al.
Publicado: (2016)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET
por: Pantaleo, Maria A., et al.
Publicado: (2010)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
por: Nanni, Patrizia, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_n90k8fadj8s0fecv210vgevr70